{"id":"NCT02603120","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-11","primaryCompletion":"2017-05-09","completion":"2019-10-23","firstPosted":"2015-11-11","resultsPosted":"2018-07-23","lastUpdate":"2020-11-12"},"enrollment":567,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"ABC/DTG/3TC","otherNames":["Triumeq®"]},{"type":"DRUG","name":"B/F/TAF","otherNames":["Bictegravir (previously referred to as GS-9883)/Emtricitabine/Tenofovir Alafenamide","Biktarvy® [BVY]"]},{"type":"DRUG","name":"ABC/DTG/3TC Placebo","otherNames":[]},{"type":"DRUG","name":"B/F/TAF Placebo","otherNames":[]}],"arms":[{"label":"Blinded Phase: B/F/TAF","type":"EXPERIMENTAL"},{"label":"Blinded Phase: ABC/DTG/3TC","type":"ACTIVE_COMPARATOR"},{"label":"Open-Label Phase","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.","primaryOutcome":{"measure":"Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"B/F/TAF","deltaMin":1.1,"sd":null},{"arm":"ABC/DTG/3TC","deltaMin":0.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.62"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":94,"countries":["United States","Australia","Belgium","Canada","France","Germany","Italy","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["31430369","29925489","39993074","36912172","29956087"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":282},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Headache","Arthralgia"]}}